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Epigenetic mechanisms have been suggested to play a role in the genetic regulation of pathways related to inflammation.Therefore,
we aimed to systematically review studies investigating the association between DNA methylation and histone modifications
with circulatory inflammation markers in blood. Five bibliographic databases were screened until 21 November of 2017. We
included studies conducted on humans that examined the association between epigenetic marks (DNAmethylation and/or histone
modifications) and a comprehensive list of inflammatory markers. Of the 3,759 identified references, 24 articles were included,
involving, 17,399 individuals. There was suggestive evidence for global hypomethylation but better-quality studies in the future
have to confirm this. Epigenome-wide association studies (EWAS) (n=7) reported most of the identified differentially methylated
genes to be hypomethylated in inflammatory processes. Candidate genes studies reported 18 differentially methylated genes related
to several circulatory inflammationmarkers.Therewas no overlap in themethylated sites investigated in candidate gene studies and
EWAS, except for TMEM49, which was found to be hypomethylated with higher inflammatory markers in both types of studies.
The relation between histone modifications and inflammatory markers was assessed by one study only. This review supports an
association between epigenetic marks and inflammation, suggesting hypomethylation of the genome. Important gaps in the quality
of studies were reported such as inadequate sample size, lack of adjustment for relevant confounders, and failure to replicate the
findings. While most of the studies have been focused on C-reactive protein, further efforts should investigate other inflammatory
markers.
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1. Introduction
Inflammation is a critical response to pathogens and injuries
in the human body. Specifically, chronic low-grade inflam-
mation plays a key role in the pathogenesis of chronic
conditions and diseases like obesity, diabetes mellitus, and
cardiovascular disease [1–3]. A better understanding of fac-
tors that contribute to the development of inflammation and
its consequences on disease is essential to improve prevention
strategies in inflammation-related disorders.
Genome-wide association studies have identified several
genetic variants associated with inflammatory markers such
as C-reactive protein, the most widely studied marker [4, 5],
but the explained variance is relatively small. In addition,
nongenetic factors such as smoking and dietary behaviours
have been shown to exhibit a strong influence on the inflam-
matory response [6, 7]. Emerging evidence suggests that
epigenetic processes, reflecting changes in gene expression
that occur without sequence mutations, may offer opportu-
nities to understand the pathophysiology of inflammation
processes.The role of epigenetic determinants is increasingly
being recognized as a link between environmental factors
and disease risk. Moreover, epigenetic modifications are also
involved in differentiation of the immune cells, a key com-
ponent of the inflammatory process. Epigenetics is defined
as a group of chemical modifications of the DNA sequence,
which could be affected by external factors such as BMI,
smoking, and inflammation and can be transmitted from
one generation of cells to the others [8]. The molecular basis
of epigenetic mechanisms is complex and comprises DNA
methylation, modifications of histones, and gene regulation
by noncoding RNAs [9]. Unlike genetic variation, epigenetic
modifications are dynamic and potentially reversible and,
therefore, could bemodified by lifestyle and other therapeutic
approaches.
Until now, a comprehensive and systematic appraisal of
the current literature on the role of epigenetic modifications
in inflammation measured by levels of inflammatory markers
is missing. Therefore, we aimed to identify and synthetize
all available evidence conducted in humans and quantify
the association of two of the major epigenetic modifications,
DNA methylation, and histone modifications, with circula-
tion inflammatory markers in blood.
2. Materials and Methods
This review was conducted and reported using a predefined
protocol and in accordance with the PRISMA [10] and
MOOSE [11] guidelines (Supplement Material S1 and S2).
We sought studies published before 21 November of 2017
(date last searched) in five electronic databases: Embase.com,
Medline (Ovid), Web-of-Science, Cochrane Central, and
Google Scholar. We did the search with the help of an expe-
rienced medical information specialist. In databases where
a thesaurus was available (Embase and Medline), articles
were searched by thesaurus terms, title and/or abstract and
in other databases, only by title and/or abstract. The search
combined terms related to the exposure (e.g., epigenetic,
hypomethylation, hypermethylation, DNA methylation, and
histone acetylation) and outcome (e.g., inflammation, C-
reactive protein, and cytokine). We did not apply any lan-
guage restriction, but we restricted the search to studies on
humans alive. The full search strategies of all databases are
provided in Supplement Material S3.The study identification
also included manual search, based on the screening of the
citations of the relevant studies.
Information about study selection and inclusion crite-
ria, data extraction process, and risk of bias assessment is
described in Supplement Material S4.
3. Results
After deduplication, we identified 3,759 potentially relevant
citations. Based on the title and abstract, 3,679 studies
were excluded due to inappropriate exposure (gene muta-
tions, gene polymorphism, and microRNA), inappropriate
outcome (autoimmune diseases, cancer, and inflammation-
related diseases such as asthma), or both. We also excluded
investigations conducted in mice or rats (n=298). Addition-
ally, we excluded studies that reported methylation levels
in inflamed body areas or inflamed cells without quanti-
tative investigation with inflammation markers, as well as
studies that assessed methylation changes before and after
immunotherapy. The final set of 80 studies were considered
for full-text assessment. Of these, 24 unique studies met our
eligibility criteria and were included in this review.The other
56 articles were excluded for reasons shown in Figure 1.
3.1. Characteristics of the Included Studies. Detailed charac-
teristics of the included studies are summarized in Tables 1–3.
All included studies were of cross-sectional design, except
one study of prospective design [12]. Overall, 17,399 individu-
als were participating in these studies. Nine studies included
participants from the USA, three studies from China, three
studies fromCanada, and the rest included participants from
Brazil, Colombia, India, Ireland, Germany, Greece, Mexico,
Spain, and Sweden. One of the studies [13] included partici-
pants from different cohorts such as USA, UK, Italy, Germa-
ny, and Netherlands. The majority (n=23) of studies assessed
epigenetic signatures in blood, whereas other assessed epige-
netic marks in tumour specimens (glioblastomas).
Of the 24 studies included, four studies assessed only
global DNA methylation, eleven studies assessed only DNA
methylation in specific candidate genes, and seven stud-
ies used genome-wide approaches. One additional study
examined both global DNA methylation and methylation in
specific candidate genes [14]. Only one study assessed histone
modification in relation to inflammation markers [15].
The most studied marker was C-reactive protein (CRP),
whichwas evaluated in 17 studies. Interleukins like IL-4, IL-6,
IL-8, IL-9, IL-10, and IL-18 were evaluated in 11 studies. TNF-
𝛼 was assessed in three studies, fibrinogen was assessed in
two studies, and othermarkers such asVCAM, ICAM,VEFG,
COX2, leptin, TNFR2, C-CAM1, alpha interferon, and TGF-
𝛽 were assessed one single time. Nine studies were judged
at medium risk of bias whereas the rest were at high risk of
bias.
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Articles identiﬁed through
electronic searching
(n=3,739)
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manual searching
(n=30)
Full-text articles excluded
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• Not the appropriate exposure
(n=22)
• Not the appropriate outcome
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Citations nor relevant based on abstract
(n=3,679)
Full-text articles retrieved for
more detailed evaluation
(n=80)
Studies included
(n=24)
Articles screened aer duplicates removed
(n =3,759)
Figure 1: Flowchart of studies included in the systematic review.
Table 1: Global DNAmethylation and inflammatory markers.
Author, Year Study design Outcome Tissue type
Population
Sex/Age/Sample
size/Country
Adjustment Main findings
LINE-1 methylation
Baccarelli et al.,
2010 [16] CS
VCAM-1, ICAM-1
and CRP WB
M /73.8 ±
6.7/n=593/USA
Age, BMI, smoking,
pack years of
smoking, IHD or
stroke.
Inverse association for
VCAM-1. No association
for ICAM-1 and CRP.
Perng et al., 2012
[17] CS CRP WBC
M andW/ 8.8 ±
1.7/n=568/
Colombia
Sex, vitamin A,
maternal BMI and
household
socioeconomic
stratum.
Higher CRP was related
to lower LINE-1
methylation.
Zhang et al., 2012
[14] CS CRP WBC
M andW/ 18-
78/n=165/USA
No association (𝛽
coefficient=-0.02,
p=0.81).
Narayan & Dangi,
2017 [18] CS CRP WB
M andW/7.9 ±
1.5/n=600/India
Sex, plasma Vitamin
A, socioeconomic
status
Global DNA
methylation was
inversely related to CRP
concentrations and the
association was stronger
in male children.
5mdC
Murphy et al., 2015
[19] CS
IL-6 (protein and
serum levels) WB
M and
W/mean=33.04/
n=47/Ireland
No association (r =
-0.125, p=0.46).
CS: cross-sectional; VCAM-1: vascular cell adhesion molecule 1; ICAM-1: intercellular adhesion molecule 1; CRP: C-Reactive protein; WB: whole blood; M:
men; BMI: bodymass index; WBC: white blood cells; IL: interleukin; W: women.
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3.2. Global DNA Methylation and Inflammatory Markers.
Five studies examined the association between global DNA
methylation and inflammatory markers in blood samples
(Table 1). Four of these studies assessed methylation in long-
interspersed nuclear element (LINE-1). A large portion of
methylation sites within the genome are found in these repeat
sequences and transposable elements and correlate well with
total genomic methylation content. From the four studies,
two [14, 16] reported no association between global DNA
methylation and CRP levels, while the other two showed
lower methylation to be related with higher CRP levels [17,
18].
One study [16], in addition to CRP levels, also evaluated
the association of global DNA methylation at LINE-1 with
VCAM-1 and ICAM-1 and reported an inverse association
with VCAM-1 but no association with ICAM-1. One study
quantified globalDNAmethylation bymeasuring the amount
ofmethylated cytokines in the sample (5mc) relative to global
cytidine (5mC + dC) in a positive control and found no
association between global DNAmethylation and IL-6 serum
levels [19].
3.3. Gene-Specific DNAMethylation and Inflammatory Mark-
ers. Twelve studies examined the relation of inflammatory
markers with methylation sites in, or near, candidate genes
(Table 2). One study measured DNA methylation in tumour
specimens [20], whereas the other studies used blood samples
to assess the DNAmethylation.
Of the twelve studies, eight did not report any level of
adjustment or control for confounders, one of them con-
trolled for age and sex [21], and the others controlled for these
two confounders plus additional ones such as diet and race
[14, 22, 23]. Of the twelve studies, three focused solely on
CRP as outcome, one solely on interleukins, and one solely on
leptin and the others assessed a set of inflammatory markers
including interleukins, TNF-𝛼, and fibrinogen.
In total, eight studies assessed CRP as inflammatory
marker. Overall, these studies found higher levels of CRP to
be associated with higher degree of methylation of SOCS-
1 [24], LY86 [22], and EEF2 [25] and higher levels of CRP
to be associated with lower degree of methylation of AIM2
[26], IL-6 [27], and IL-6 promoter gene [21]. One additional
study that examined methylation levels of IL-6 promoter and
CRP reported no association [14]. In addition, no association
was found between methylation status of F2RL3 in peripheral
blood cells and CRP levels.
Five studies evaluated the association of gene-specific
DNA methylation with IL-6. They found higher degree of
methylation of MGMT, RAR𝛽, RASSF1A, and CDH13 in
tumour specimens and of SOCS-1 in peripheral blood with
higher levels of IL-6, while others found less degree of
methylation of USP2, TMEM49, SMAD3, DTNB, and IL-6
promoter with higher levels of IL-6. Other interleukins such
as IL-8, IL-10, and IL-18 were only evaluated once [20, 23, 28].
No significant correlation was found for IL-8, whereas for IL-
10 and IL-18 inverse association was found with DNAmethy-
lation in IL-10 promoter and F2RL3, respectively (Table 2).
Two studies evaluated leptin as outcome, showing con-
tradictory results. One reported inverse association between
leptin levels and Leptin Receptor methylation [25], whereas
the other reported no association between Leptin promoter
and leptin levels [29].
Two studies assessed the association of DNAmethylation
and TNF𝛼 levels. Higher levels of methylation of EEF2 [25]
and SOCS-1 [24] were found with higher levels of TNF𝛼.
Additionally, six studies reported the association between
methylation at different genes (MGMT, RAR𝛽, RASSF1A,
CDH13, USP2, TMEM49, EEF2, COL18A1, IL4I1, LEPR,
PLAGL1, IFRD1, MAPKAPK2, PPARGC1B, SMAD3, DTNB,
LY86, and F2RL3) with levels of several inflammatory mark-
ers other than CRP and interleukins (VEGF, VCAM1, C-
CAM1, COX-2, sTNFR2, and fibrinogen) (Supplement Table
1).
3.4. Epigenome-Wide Analysis and Inflammatory Markers.
Seven studies investigated differentially methylated regions
in the genome in a hypothesis-free approach. Six of them
adjusted at least for age and sex. Of these six, four adjusted
additionally for BMI, smoking, and/or other confounders. All
of the studies used blood samples to assess DNAmethylation.
One study assessed 121 biomarkers related with inflam-
mation, cancer, and cardiovascular disease [30] and five
studies assessed CRP. The remaining two studies evaluated
TNF and interleukins such as IL-1𝛽, IL-6, IL-8, and IL-10
[31, 32] (Table 3).
Three out of seven studies used replication to validate
their findings: two of them [13, 33] used external validations
and one [34] internal validation.
The identified genes were enriched by pathways such
as atherosclerosis, IL-6, IL-9, IL-8, growth hormone, and
JAK/STAT signalling pathways.
Among the genes reported to be differentiallymethylated,
SOCS3 and BCL3 were found to be significantly hypomethy-
lated in two studies [13, 33]. BCL3was no longer significant in
the replication cohort, whereas SOCS3 remained significant
after replication.
3.5. Histone Modifications and Inflammatory Markers. Only
one study examined the association between histone modifi-
cations and inflammatory markers [15].The authors assessed
levels of acetylated histone H4 in the peripheral blood
mononuclear cells of Chronic Obstructive Pulmonary Dis-
ease (COPD) patients and reported higher acetylation levels
in patients with higher IL-8 levels and in patients with lower
IL-4 levels.
4. Discussion
This is the first attempt to summarize current literature on
the role of epigenetic marks in chronic inflammation. There
is suggestive evidence for hypomethylation of overall genome
in inflammatory processes, but better-quality studies have to
confirm these results. Histone modification and inflamma-
tory markers are scarcely investigated. Given the complexity
and variability of proteins involved in the inflammation
network, most of the studies focused on exploring CRP levels
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with few studies on IL-6 and fewer investigations on IL-
8, IL-10, IL-18, VEGF, Cox-2, TNF-𝛼, sTNFR2, leptin, and
fibrinogen levels. The largest epigenome-wide association
study up to date found AIM2 and SOCS3 to be top genes
related to CRP levels in whole blood.
4.1. Global DNA Methylation. There were either no or an
inverse association of inflammatory markers such as CRP,
VCAM-1, and ICAM-1 in whole blood. Because we identified
only a small number of studies, we cannot make any firm
inferences on the overall hypomethylation of the genome
due to inflammation. Moreover, populations were hardly
comparable as two of the studies were conducted on children
while the others on adults. As global DNA hypomethylation
has become the hallmark of most human cancers, stroke, and
heart disease [35–38], the need to measure this epigenetic
signature has become more essential. Global methylation
would enable the ability to associate, for example, LINE-
1 or 5-mdC levels, with correlative factors such as patient
history or clinical outcome. The observed hypomethylation
could lead to activation of dormant repeat elements and
the subsequent aberrant expression of associated genes or
may contribute to genomic instability and increasedmutation
rates.More intense efforts in studies investigating globalDNA
methylation through different methodologies such as Alu
repeats and LUMA can hold future prospects for guiding risk
stratification in individuals with high levels of inflammatory
markers at an increased risk of chronic diseases.
4.2. EWAS vs. Candidate Gene Approaches. Ligthart et al.
identified and validated 58 CpG sites located in 45 unique
loci in whole blood among 12,974 individuals of European
and African descent [13]. The top signal near AIM2 gene was
found to be inversely associated with gene expression levels
and with lower CRP levels. AIM2 is a key regulator of human
innate immune response implicated in defence mechanism
against bacterial and viral pathogens [39, 40]. Several of these
hits including cg18181703 (SOCS3), cg06126421 (TUBB), and
cg05575921 (AHRR) were associated with future incidence of
coronary heart disease and smoking [13], whereas two other
CpGs were recently identified in an EWAS of type 2 diabetes
[41]. The gene SOCS3, suppressor of cytokine signalling
3, plays a pivotal role in the innate immune system as a
regulator of cytokine signalling along the JAK/STAT pathway
and was previously reported to have an important role
in the processes of atherosclerosis [42]. Moreover, another
epigenome-wide association study conducted among 1,741
individuals of European descent reported SOCS3, among
others, to be significantly associatedwith systemicCRP levels,
not only in peripheral blood tissue, but also in human liver
tissue [33].
Given the reported association of CRP levels and these
cardiometabolic clinical outcomes, it seems that inflam-
mation-related epigenetic features may explain part of the
observed associations reported in epidemiology. However,
the results should be interpreted with caution, as the asso-
ciation of CRP and DNA methylation were not adjusted
for these factors. Most of the replicated CpG sites reported
in the study of Lighart et al. were associated with differ-
ent cardiometabolic phenotypes (body mass index, fasting
glucose, fasting insulin, triglycerides, total cholesterol, and
HDL-cholesterol), highlighting the evidence of a pleiotropic
network of epigenetics across various phenotypes.This infor-
mation is promising as it holds new insights into shared
epigenetic mechanisms and provides opportunities to link
the inflammation processes with clinical outcomes. More-
over, two large cohorts (KORA and GENOA) observed
hypomethylation to be related with higher levels of CRP
[33, 43]. The latter, reported a similar trend of hypomethy-
lation among individuals of older age and suggested that
these patterns of modifications of DNA methylation on
CpG islands between aging and inflammatory markers may
indicate shared molecular mechanisms underlying chronic
diseases through epigenetic changes [43].
Differentially methylated genes associated with CRP
levels and other inflammatory markers did not directly
overlap with the genes identified from previously reported
genome-wide association studies influencing CRP levels
and other biomarkers. The nonoverlap between GWAS and
EWAS identified genes shows that clinical phenotypes are
being influenced by different molecular mechanism, all of
them important to explain phenotypical variation. Most of
the identified genes are involved in common inflammation
pathways related to cancer, rheumatic diseases, and gas-
trointestinal pathologies [24, 27]. Nevertheless, candidate
gene approaches have less stringent criteria to assign signif-
icance on the expense of a narrower focus on genes. This
might explain the absence of reproducibility of results in
the reviewed epigenome-wide association studies, except for
TMEM49, which was found to be inversely associated with
sTNFR2 and IL-6 levels in the candidate gene approach study
of Smith et al, and shared the same direction of association
with CRP levels, in the EWAS study of Lighart et al.
4.3. Histone Modification. This review demonstrated that
evidence involving inflammation and histone modifica-
tion mechanisms are inexistent. Histone modifications are
another epigenetic mark that play a pivotal role in the
epigenetic regulation of transcription and other functions in
cells. In addition, histone modifications have been linked to
other inflammatory-related disorders, such as dyslipidaemia,
obesity, diabetes, cancer, and cardiovascular disease [44–46].
Future studies on histone modifications and inflammation
markers might shed light on their functional role in chronic
diseases and might provide novel target therapies for inflam-
matory conditions.
4.4. Bias, Confounding, and Tissue Specificity. There is quite
ample evidence showing differential DNA methylation dif-
fering by ethnicity [47]. Therefore, it is recommended that
studies investigating epigenetics of genes related to inflam-
mation should replicate their findings in diverse populations.
The largest to date epigenome-wide association study inves-
tigating DNA methylation and CRP levels used as discovery
set a large European population (n = 8,863) and sought
transethnic replication in African Americans (n = 4,111) [13].
As in genetic studies, the importance of replication of the
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significant findings in epigenetic association studies is a
paramount in order to prevent false-positive results [48, 49].
Unlike genetic association studies that are less prone to
confounding, epigenetic signatures throughout the genome
are highly labile due to temporal or spatial factors affecting
DNA such as age, gender, demographics, lifestyle, comor-
bidities, and medication use. It has been shown that methy-
lation investigations harbour new information in explain-
ing the variation of complex traits such as inflammation
characterized by a strong influence of environment [4, 13,
50]. Inflammatory markers such as CRP, one of the most
studied, are affected by both genetic and environmental
factors. Therefore, controlling for confounders in epigenetic
studies is crucial. In our review, the majority of our studies
(62.5%) were classified as low quality largely explained by
the lack of proper adjustment in the statistical models. While
epigenome-wide studies controlled for life-style factors such
as smoking, alcohol consumption, and BMI, candidate-gene
approach studies were heavily suffering from incomplete
adjustments.
Most of the inflammatory markers, and especially the
ones of the acute phase, are predominantly synthesized in
liver cells and hepatocytes and are regulated via transcription
factors such as STAT3, C/EBP family members, and NF-
kappa B by the proinflammatory cytokines IL-6 and IL-1𝛽 [51,
52]. Nevertheless, extrahepatic expression to a lesser degree
has been reported for adipose tissue and blood cells [52].
DNA methylation profiles have been commonly studied in
whole blood due to the easy access to the biological samples.
Environmental exposure signatures such as smoking, alcohol,
and other conditions involving the circulatory system and
the immune response are well reflected in whole blood. This
tissue is primarily composed of leukocytes, a key component
of the human immune system and, therefore, highly relevant
to systematic inflammation. However, since peripheral blood
constitutes a heterogeneous admixture of different cell pop-
ulations, it is possible that the results reflect inflammation-
related DNA methylation changes that influence a single cell
type component of blood cells. Adjusting for measured or
estimated blood cell proportions, or future studies conducted
in cell specific tissues, would help to rule out presence of any
residual confounding caused by white blood cell distribution.
4.5. Causality and Study Designs. In the last years, the GWAS
have resulted in the identification of many genetic variants
that are associated with clinical traits and diseases. However,
together, these variants explain only a small fraction of the
variability. It has been suggested that epigenetics might hold
promise to uncover the rest of the missing heritability. More-
over, it has been commonly hypothesized that epigenetic
signatures are a cause for disease, rather than consequence.
With the current evidence, it is unclear if epigenetic variation
is causal to these inflammatory markers. In a recent study of
Ahsan et al, the authors investigated the genetic and epige-
netic influence in a large set of disease-related inflammatory
markers [30]. Combining results of GWAS/EWAS in around
1,069 individuals and employing a complex bidirectional
model to asses causality between genetic variation-DNA
methylation-inflammation markers, it was concluded that
DNAmethylation has a limited direct effect on inflammatory
markers. It reflects the underlying pattern of genetic variants,
environmental exposures or secondary effect of the disease
pathogenesis. In line with recent evidence, rather than a
cause,DNAmethylation seems to be a consequence of clinical
traits, such as BMI [53].
All of the included studies in this systematic review were
of cross-sectional design, except for one [47], meaning that
both epigenetic signatures and outcomes were measured at
the same time. This design challenges further inferences
concerning causal relation, a typical vulnerability of epi-
genetic studies. In longitudinal cohort designs, repeated
measurements for both inflammatory markers and dynamic
methylation changes could improve our knowledge of the
directionality of events. Furthermore, statistical approaches
like Mendelian Randomization, in which genetic variants are
used as proxies for DNA methylation and the outcome of
interest, offer new opportunity to investigate the direction-
ality of evidence from cross-sectional data [54]. The identi-
fication, directionality, and molecular pathways underlying
the relation between epigenetic signatures and inflammatory
markers represent promising targets for future functional
studies.
4.6. Epigenetic Screening. In the last years, many advances
in technologies related to measurements of epigenetic sig-
natures have been developed to respond to the fast-growing
pace of the field [55]. These techniques allow the investi-
gation of DNA methylation either on candidate genes or
on the whole-genome level. However, as the number of
genes of interest increases along with the number of tissues
of relevance, investigating the role of DNA methylation in
different clinical traits could be very costly and time con-
suming. Progressing to more cost-effective solutions, high-
throughput technologies have open new opportunities for
epigenome-wide investigations in large-scale screening such
as in population-based cohort studies. Furthermore, gene-
specific assays such as bisulfite conversion provide a quick
and efficient result for epigenetic investigations requiring
relatively low DNA input with minimum DNA loss [56,
57]. Cloning, the gold standard method for gene-specific
DNA methylation studies, followed by Sanger sequencing is
another technological option [58]. Although the time for the
procedure has been significantly reduced, the sequencing step
might introduce several sources of errors [55, 59]. Another
technique, pyrosequencing, represents a high throughput
quantitative method used for bisulfite sequencing [60, 61].
This technique, which can be used for both DNA methyla-
tion and genetic variation (single nucleotide polymorphism)
analysis, takes less time than cloning providing accurate reads
within each run. Yet, optimal DNA quality is important to
avoid misreads of pyrosequencing [55]. Mass spectrometry
assay, on the other side, is a tool that can be used for the
discovery and quantification of DNAmethylation sites based
on difference in fragments weights that have been cleaved
depending on the methylation status [59]. This technology
is highly sensitive and has the ability to sequence reads up
to 600 bp, which is considerably longer than other methods.
Quantitative Polymerase Chain Reaction (qPCR) arrays are
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another alternative of methylation quantification techniques
operating on fluorophore-labelled probes that emit fluores-
cence when bound to a complementary DNA sequence.
This method might not be ideal for regions with multiple
CpG sites because many probes need to be created, resulting
rather costly. However, if a region is characterized by a few
CpGs, qPCR method might provide a simple and relatively
inexpensive way to conclude a high-powered study [55].
Other chip techniques for epigenetic studies, in particular
for histone modifications, include chromatin immunopre-
cipitation (ChIP), methylated DNA immunoprecipitation
(MeDIP) platforms, and methyl-binding protein immuno-
precipitation platforms. A major limitation to these tech-
niques in epigenome-wide analysis is the quality of the anti-
body, which plays an important role in the proper enrichment
of DNA. In general, the immunoprecipitation techniques
require the availability of large sample volumes and only
measure relative enrichment of epigenetic markers.
Concerning large-scale epigenetic analysis, the most
widely used platforms, as shown from our review, are
from Illumina. Illumina methylation profiling is based on
bisulfite converted DNA genotyping [62]. For example, The
Illumina Infinium HumanMethylation27 (27,000 CpG site)
andHuman-Methylation450Bead (450,000CpG sites) arrays
provide genome-wide coverage, featuring methylation sta-
tus at CpG islands, CpG shores, non-CpG sites, promoter
regions, 5󸀠 UTR, 3󸀠 UTR, and gene bodies. More recent
platforms, such as Infinium MethylationEPIC BeadChip Kit,
have increased the number of interrogated sites to more
than 850,000 CpGs across the genome at single-nucleotide
resolution for only of 250 ng DNA as input quantity [63].
Moreover, TruSeq Methyl Capture EPIC Library Prep Kit,
is another option that combines whole-genome bisulfite
sequencing with methylation arrays that can support both
screening and biomarker discovery studies targeting over 3.3
millionCpGs [64].These technologies rapidly produce a large
amount of data at relatively low costs and aremostly preferred
in population studies. On the other hand, epigenome-wide
sequencing is another technology that is holding high hopes
for future discoveries in the field of epigenetics. Currently,
its widespread use is hampered by the high costs and
computation burden of the analysis.
4.7. Clinical Implications. Understanding the epigenomic
regulation of loci related to inflammatorymarkersmight hold
the possibility of discovering attractive targets for control-
ling inflammatory processes and, consequently, improving
therapeutic interventions for chronic diseases that share in
their aetiology, inflammatory-related pathophysiology. The
identified epigenetic patterns may be used not only in
functional studies to provide further insights into molecular
mechanisms of inflammatory processes but also in biomarker
studies using whole blood to improve the prediction of
inflammation-related clinical disorders or events.
5. Conclusions
Current evidence suggests a potential role of epigenetics
on the level of inflammatory markers in blood. Studies
reporting on the association of inflammation with global
DNA methylation show a hypomethylation trend. However,
this evidence is not conclusive. Further studies are recom-
mended to explore this relation. Moreover, studies on the
role of histone modifications in inflammation markers are
scarce. While most of the studies have been focused on CRP,
reporting replicated genes across cohorts such as SOCS3,
further efforts should focus on other biomarkers of the
inflammatory cascade such as interleukins.Most importantly,
given the systemic nature of inflammation, validation of the
methylation sites among different tissues is paramount. The
identified and reported genes so far involve epigenetics of
inflammation with cardiometabolic factors, but also cancer
and rheumatic diseases highlighting the potential of these
regions as translational targets in the future. Given that we
observed a lack of high quality investigations included in this
review, we recommend future studies to improve some of the
most urging factors such as an appropriate study design. This
might be done by involving repeated measurements or with a
prospective design that would allow drawing insights on one
of themost important drawbacks of epigenetic data, assessing
the directionality of the effects. Another important aspect to
improve is to increase the sample size in order to provide
adequate power and to performproper adjustment of analysis
to account for the role of environment on both epigenetics
and inflammation. Lastly, the identified genes need to be
validated in functional (in vitro and in vivo) studies in order
to draw valuable and conclusive insights into the epigenetic
mechanisms of inflammatory markers.
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